Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

 
• By Mandy Jackson

Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.

Digital illustration of Cancer cell in colour background

More from Strategy

More from Business